

Plasmodium falciparum, Strain W2mef

Catalog No. MRA-615

Product Description:

Plasmodium falciparum (*P. falciparum*), strain W2mef is a mefloquine-resistant clone derived from clone W2 after *in vitro* passage in mefloquine. Strain W2 was cloned from the Indochina III/CDC isolate originally derived from a Laotian patient who failed chloroquine therapy. MRA-615 was produced by cultivation of seed material in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (volume per volume) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 grams per liter D-glucose, 0.005 micrograms per mL hypoxanthine and 2.5 micrograms per mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia for 18 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.

Lot: 70043270

Manufacturing Date: 20APR2021

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Identification by Giemsa Stain Microscopy ¹	Blood-stage parasites present	Blood-stage parasites present
Antimalarial Susceptibility Profile (<i>in vitro</i>) ¹ Half-maximal Inhibitory Concentration (IC ₅₀) by SYBR green I [®] drug sensitivity assay ² Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine	Report results Report results Report results Report results Report results Report results	37.4 ± 0.9 nM 5.7 ± 0.3 nM 114.4 ± 5.3 nM 1451 ± 337.1 nM 26260 ± 1815 nM 317000 ± 29238 nM
Genotypic Analysis ¹ Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 790 base pairs)	Consistent with <i>P. falciparum</i>	Consistent with <i>P. falciparum</i> (Figure 1)
Functional Activity by PCR Amplification ¹ MSP2 PCR amplicon analysis	600 to 900 base pair amplicon	~ 900 base pair amplicon
Level of Parasitemia by Giemsa Stain Microscopy Pre-freeze (18 days post-infection) ³ Ring-stage parasitemia Total parasitemia Post-freeze (4 days post-infection) ¹ Ring-stage parasitemia Total parasitemia	Report results ≥ 2% Report results ≥ 1%	3.16% 5.38% 0.55% 3.03%
Viability (post-freeze; 1 day post-infection) ¹	Growth in infected red blood cells	Growth in infected red blood cells
Sterility (21-day incubation) ¹ Harpo's HTYE broth, 37°C and 26°C, aerobic ⁴ Trypticase soy broth, 37°C and 26°C, aerobic Sabouraud broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep blood agar, 37°C, aerobic Sheep blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth

TEST	SPECIFICATIONS	RESULTS
Mycoplasma Contamination¹ DNA detection by PCR	None detected	None detected

¹Testing completed on vial, post-freeze material

²A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (greater than 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.beiresources.org/Publications/MethodsInMalariaResearch.aspx>.]

³Testing completed on bulk material prior to vialing and freezing

⁴Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-615 MSP2 Sequence

```

ATATTAAAAA TGAAAGTAAA TATAGCAACA CATTCATAAA CAATGCTTAT AATATGAGTA TAAGGAGAAG TATGGCAAAT
GAAGGTTCTA ATACTACTAG TGTAGGTGCA AATGCTCCAA ATGCTGATAC TATTGCTAGT GGAAGTCAAA GTAGTACAAA
TAGTGCAAGT ACTAGTACTA CTAATAATGG AGAATCACAA ACTACTACTC CTACCGCTGC TGATACTATT GCTAGTGGAA
GTCAAAGGAG TACAAATAGT GCAAGTACTA GTACTACTAA TAATGGAGAA TCACAAACTA CTACTCCTAC CGCTGCTGAT
ACTATTGCTA GTGGAAGTCA AAGGAGTACA AATAGTGCAA GTACTAGTAC TACTAATAAT GGAGAATCAC AAACACTACTAC
TCCTACCGCT GCTGATACCC CTACTGCTAC AGAAAGTAAT TCACCTTCAC CACCCATCAC TACTACAGAA AGTTCAAGTT
CTGGCAATGC ACCAAATAAA ACAGACGGTA AAGGAGAAAG GAGTGAAAAA CAAAATGAAT TAAATGAATC AACTGAAGAA
GGACCCAAAG CTCCACAAGA ACCTCAAACG GCAGAAAAATG AAAATCCTGC TGCACCAGAG AATAAAGGTA CAGGACAACA
TGGACATATG CATGGTTCTA GAAATAATCA TCCACAAAAT ACTTCTGATA GTCAAAAAGA ATGTACCGAT GGTAACAAAG
AAACTGTGG AGCAGCAACA TCCCTCTTAA ATAACCTCTAG TAATATTGCT TCAATAAATA AATTTGTTG

```

/Heather Couch/

Heather Couch

05 JUN 2021

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

